Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 8/20 | 0.41 |
| ▸ | JUN | P05412 | 4/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.41 |
| ▸ | RELA | Q04206 | 4/20 | 0.41 |
| ▸ | ASPH | Q12797 | 1/20 | 0.41 |
| ▸ | XPO1 | O14980 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | ATF1 | P18846 | 5/20 | 0.36 |
| ▸ | FOS | P01100 | 2/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8697289 | 0.86 | NFKB1 (0.41) | KEAP1NFE2L2NFKB1JUNNFKB2 | |
| SCHEMBL26150387 | 0.84 | NFKB1 (0.40) | NFKB1JUNNFKB2RELAXPO1 | |
| SCHEMBL4277489 | 0.82 | KEAP1 (0.41) | KEAP1NFE2L2NFKB1JUNNFKB2 | |
| SCHEMBL28874828 | 0.80 | MAPT (0.44) | NFKB1JUNNFKB2RELALMNA | |
| SCHEMBL3283505 | 0.80 | ASPH (0.42) | NFKB1JUNNFKB2RELAASPH | |
| SCHEMBL8544671 | 0.80 | XPO1 (0.42) | NFKB1JUNNFKB2RELAASPH | |
| SCHEMBL28044658 | 0.79 | ASPH (0.41) | NFKB1JUNNFKB2RELAASPH | |
| SCHEMBL2352570 | 0.79 | HPGD (0.53) | NFKB1JUNNFKB2RELAASPH | |
| SCHEMBL30574458 | 0.77 | NFKB1 (0.58) | NFKB1JUNNFKB2RELALMNA | |
| SCHEMBL131646 | 0.77 | NFKB1 (0.58) | NFKB1JUNNFKB2RELALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132127-A1 | NOVEL SPIRO COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2026-05-14 | — | — | US | disclosed |
| CN-118176179-A | Novel spiro compounds | 田边三菱制药株式会社 | 2024-06-11 | — | — | CN | disclosed |
| US-11976083-B2 | Inhibitors of peptidylarginine deiminases | GILEAD SCIENCES, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| CN-115551862-B | Macrocyclic inhibitors of peptidyl arginine deiminase | 吉利德科学公司 | 2024-04-12 | — | — | CN | disclosed |
| WO-2023074847-A1 | NOVEL SPIRO COMPOUND | 田辺三菱製薬株式会社 | 2023-05-04 | — | — | WO | disclosed |
| EP-4143189-A1 | MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20230002412-A1 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. | 2023-01-05 | — | — | US | disclosed |
| CN-115551862-A | Macrocyclic inhibitors of peptidyl arginine deiminase | 吉利德科学公司 | 2022-12-30 | — | — | CN | disclosed |
| WO-2021222353-A1 | MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| EP-3712149-A1 | BENZAMIDE DERIVATIVE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING INFLAMMATORY DISEASE CONTAINING SAME AS ACTIVE INGREDIENT | Seoul National University R & DB Foundation (KR) | 2020-09-23 | — | — | EP | disclosed |
| EP-2903965-A1 | N-PROP-2-YNYL CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS | Orion Corporation (FI) | 2015-08-12 | — | — | EP | disclosed |
| WO-2014053694-A1 | N-PROP-2-YNYL CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS | ORION CORPORATION (FI) | 2014-04-10 | — | — | WO | disclosed |
| EP-1479671-B1 | Pyrimidinone compounds | SMITHKLINE BEECHAM PLC (GB) | 2009-05-27 | — | — | EP | disclosed |
| CN-101374817-A | Trisubstituted amine compounds as inhibitors of cholesteryl ester transfer protein CETP | MITSUBISHI TANABE PHARMA CORP (JP) | 2009-02-25 | — | — | CN | disclosed |
| CN-101321751-A | Met kinase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2008-12-10 | — | — | CN | disclosed |
| US-7115616-B2 | Pyrimidinone compounds | SMITHKLINE BEECHAM PLC (GB) | 2006-10-03 | — | — | US | disclosed |
| US-6953803-B1 | 1-[(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)]-2-(4-fluorobenzyl)thio-5-(1-methyl-4-pyrazolylmethyl)pyrimidin-4-one; enzyme inhibitors of lipoprotein associated phospholipase A2 (Lp-PLA2); atherosclerosis | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-10-11 | — | — | US | disclosed |
| US-20040167142-A1 | Pyrimidinone compounds | SMITHKLINE BEECHAM P.L.C. | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11976083-B2 | Inhibitors of peptidylarginine deiminases | PADI4, PADI2, PADI1 | KEAP1 1965/4885NFE2L2 2760/4885NFKB1 2124/4885 |
| US-20230002412-A1 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | PADI4, PADI2, PADI1 | KEAP1 1965/4885NFE2L2 2760/4885NFKB1 2124/4885 |
| US-20260132127-A1 | NOVEL SPIRO COMPOUND | TRHR, NR3C2, THRB | KEAP1 911/4885NFE2L2 1705/4885NFKB1 2906/4885 |
| US-20040167142-A1 | Pyrimidinone compounds | LPL, LIPG, PCSK9 | KEAP1 1338/4885NFE2L2 1717/4885NFKB1 2283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.